NT5E and dermatitis: We suggest CD73 is a potential therapeutic target for improving T cell–mediated dermatitis—one of the most common symptoms in Treg deficiency–associated primary immune deficiency diseases, such as IPEX syndrome, IPEX-like syndrome, and other autoimmune diseases related to Treg dysfunction.4